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Background. The incretin eﬀect is impaired in patients with type 2 diabetes. Aim. To assess the relation between the incretin
hormone GLP-1 and the prediabetic subtypes: impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and the
combined IFG/IGT to investigate whether a low GLP-1 response may be a predictor of prediabetes in adults. Method. 298
articles were found using a broad search phrase on the PubMed database and after the assessment of titles and abstracts
19 articles were included. Results and Discussion. Studies assessing i-IFG/IFG and i-IGT/IGT found both increased,
unaltered, and reduced GLP-1 levels. Studies assessing IFG/IGT found unaltered or reduced GLP-1 levels. When assessing
the ﬁve studies with the largest sample size, it clearly suggests a decreased GLP-1 response in IFG/IGT subjects. Several
other factors (BMI, glucagon, age, and nonesteriﬁed fatty acids (NEFA)), including medications (metformin), may also
inﬂuence the secretion of GLP-1. Conclusion. This review suggests that the GLP-1 response is a variable in prediabetes
possibly due to a varying GLP-1-secreting proﬁle during the development and progression of type 2 diabetes or diﬀerence
in the measurement technique. Longitudinal prospective studies are needed to assess whether a reduced GLP-1 response is
a predictor of diabetes.
1. Introduction
The number of people diagnosed with diabetes globally was
increased from 108 million adults in 1980 to an estimated
422 million in 2014 [1]. Thus, the global prevalence of dia-
betes has increased from 4,7% to 8,5% from 1980 to 2014
[1]. Diabetes causes complications with a 2-3 times higher
rate of cardiovascular disease, a 10–20 times higher rate
of lower extremity amputations, and a 10 times higher
incidence of end-stage renal disease in diabetic adults com-
pared to nondiabetic adults [1]. Along with this, diabetic
retinopathy caused 2,6% of total blindness and 1,9% of total
moderate or severe visual impairment globally in 2010 [1].
In addition to these complications, diabetes entails eco-
nomic costs for both the individual and the health systems
[1] and the global cost of diabetes for 2015 was estimated to
be US$1,3 trillion corresponding to 1,8% of global gross
domestic product (GDP) [2]. Further knowledge about
aetiology and pathogenesis could contribute to turn over
this development.
When glucose is orally ingested, it elicits a much
greater insulin response (two- to threefold) than if glucose
is intravenously injected to give the same blood glucose
level. This phenomenon is called the incretin eﬀect and is
due to the secretion of glucagon-like peptide 1 (GLP-1)
and glucose-dependent insulinotropic peptide (GIP) which
increases the glucose-induced insulin secretion [3]. In
patients with type 2 diabetes, the incretin eﬀect is impaired
[4]. In addition to that, studies concerning GLP-1 secretion
in patients with type 2 diabetes during an oral glucose tol-
erance test (OGTT) have observed both unaltered [5, 6]
and reduced [7] GLP-1 responses, suggesting a varying
GLP-1-secreting proﬁle during the development and pro-
gression of type 2 diabetes [5, 7] or diﬀerence in the mea-
surement technique [8]. This is further supported by the
observation that several factors (BMI, glucagon, age, and
nonesteriﬁed fatty acids (NEFA)), including medications
(metformin), inﬂuence the secretion of GLP-1 [6].
The biggest study to date—a large Danish study—
published in 2015, involving 1462 individuals, demonstrated
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a reduced GLP-1 response to an OGTT in prediabetes,
screen-detected type 2 diabetes, and obese and overweight
individuals compared to normal glucose-tolerant individ-
uals and normal weight individuals, respectively [9]. Indi-
viduals diagnosed with prediabetes are at an increased
risk of developing type 2 diabetes, with a yearly progres-
sion rate of 3,5%–7,0% in individuals with prediabetes
compared to a yearly progression rate of 2% in normo-
glycemic individuals [10]. In continuation to that, a
reversing of the prediabetic state towards normal glucose
regulation is associated with an up to 56% lower risk of
developing type 2 diabetes compared to individuals remain-
ing prediabetic [10]. Further knowledge about aetiology and
pathophysiology of prediabetes and the progression to type
2 diabetes might help in preventing and treating both states
[9, 11]. Additionally, more extensive knowledge could help
improve the diagnostic criteria concerning the subtypes of
prediabetes [11].
Therefore, this review will assess the relation between
the incretin hormone GLP-1 and the prediabetic state and
investigate whether GLP-1 may be a predictor of prediabetes
in adults.
2. Research Question
Is a low GLP-1 response a predictor of prediabetes in adults?
3. Materials and Methods
This review is a literature study using the electronical
PubMed database to ﬁnd relevant literature. Only articles in
English were included. The following search phrase in
PubMed was used:
(GLP-1) AND (prediabet∗OR pre-diabet∗OR
“impaired glucose tolerance” OR “impaired glucose tolerant”
OR IGT OR “impaired fasting glucose” OR “impaired fasting
glycaemia” OR IFG OR intermediate hyperglycaemia).
The last search update was conducted on 10 March 2017.
Articles were included which investigated the relation-
ship between GLP-1 and the diﬀerent subtypes of predia-
betes: impaired fasting glucose (IFG), impaired glucose
tolerance (IGT), and the combined IFG/IGT.
The search identiﬁed 298 articles. These 298 articles
were ﬁrst evaluated based on their title, and irrelevant
articles, in relation to the inclusion criteria and articles
in languages other than English, were excluded. Articles
with inadequate or indeﬁnite titles were included for fur-
ther evaluation. Articles being irrelevant in proportion to
answering the research question was excluded. For example,
articles investigating the impact of surgical or pharmaco-
logical interactions on the GLP-1 response and articles
not involving prediabetic subjects. Articles assessing GLP-1
alterations in adolescents were also excluded.
Finally, this resulted in 60 articles. These 60 articles were
evaluated based on their abstracts, and relevant articles ful-
ﬁlling the inclusion criteria were read and included in the
review. Included articles in the review are 19. A ﬂowchart
of the search process is illustrated in Figure 1.
4. GLP-1 and Prediabetes: Is There a
Connection?
4.1. GLP-1—An Incretin Hormone. The incretin eﬀect is
mediated by the incretin hormones—the two major being
GLP-1 and GIP. GLP-1 is a gut peptide secreted from
open-type enteroendocrine L cells—located in the intestinal
mucosa—in response to ingested nutrients (carbohydrate,
protein, and fat). This is thought to be the primary stimulus
for secretion, and the secretory response depends on both
meal size and gastric emptying rate. Neuronal and hormonal
mechanisms have also been proposed regarding the regula-
tion of secretion [3].
GLP-1 comes in diﬀerent isoforms (see Figure 2): unami-
dated GLP-1(1–37), GLP-1(7–37), and GLP-1(9–37), and
amidated GLP-1(1–36)NH2, GLP-1(7–36)NH2, and GLP-
1(9–36)NH2 [8]. In human, the amidated isoforms are the
predominant [8, 12]. GLP-1(7–36)NH2 and GLP-1(7–37)
are termed “active/intact” GLP-1 and when secreted,
both conﬁgurations of the hormone are rapidly degraded
(T1/2 = 1-2min) by the enzyme dipeptidyl peptidase 4
(DPP-4) to GLP-1(9–36)NH2 and GLP-1(9–37), respec-
tively, leaving only around 10–15% of the “active/intact”
GLP-1 in the systemic circulation [3, 5, 12, 13]. Furthermore,
GLP-1 is metabolised by the enzyme neutral endopeptidase
24.11. [12, 13]. GLP-1(7–36)NH2, GLP-1(7–37), and the
metabolites GLP-1(9–36)NH2 and GLP-1(9–37) are termed
“total” GLP-1 [12, 13]. “Active/intact” GLP-1 only accounts
for the endocrine eﬀect of GLP-1, whereas GLP-1 is also
thought to have neural eﬀects, whereby measuring “total”
GLP-1 mirror the total eﬀect of GLP-1 better [12]. Further-
more, since the concentration of “active/intact”GLP-1 is very
low (0–15pmol/l) and rises only very little in response to
small meals, it is harder to detect a diﬀerence in secretion
compared to the measuring of “total” GLP-1 ranging from
5 to 80 pmol/l [5, 8, 12, 13]. Therefore, it has been argued that
measuring “total” GLP-1 is best, when GLP-1 secretion
should be measured [5, 8, 12–14]. In α cells, processing
of the proglucagon (PG) gene leads to the secretion of
small amounts of the biologically inactive peptides GLP-
1(1–36)NH2 and GLP-1(1–37) [12]. Due to cross-reactivity
and the varying commercially available assays, knowledge
of this plethora of peptides and their metabolites is impor-
tant, when assessing the assays used to measure their plasma
concentrations [8, 12].
Besides increasing insulin secretion, GLP-1 also has
other eﬀects, including inhibition of glucagon secretion
from α cells; stimulating, potential proliferating, and antia-
poptotic eﬀects on β cells; a delay of gastrointestinal secre-
tion and motility; an appetite-reducing eﬀect; a potential
advantageous eﬀect on the cardiovascular system; and a
potential neurotropic or neuroprotective eﬀect [3, 13].
Given that a lot of these eﬀects are advantageous in the
scope of treating diabetes, the use of incretin-based thera-
pies is increasing [3].
4.2. Prediabetes—Not Just One Condition. Prediabetes is an
overall term to describe the dysglycemic conditions between
normal glucose tolerance (NGT) and the diabetic state. The
2 Journal of Diabetes Research
diﬀerent subtypes of prediabetes consist of isolated impaired
fasting glucose (IFG), isolated impaired glucose tolerance
(IGT), and the combined state IFG/IGT [10, 11]. An estima-
tion of theworldwide prevalence of individuals with prediabe-
tes is approaching 840 million [10]. Since people with
prediabetes are at an increased risk of developing diabetes
compared to non-prediabetic individuals—as mentioned
above—screening for the prediabetic state, and thereby initiat-
ing prevention of development of diabetes, is a health goal
[10].This is further supported by studies showing an increased
risk of micro- and macrovascular complications with predia-
betes, exempliﬁed by a study showing that 8% of nondiabetic
participants in a cross-sectional analysis had diabetic reti-
nopathy, and an increased risk of cardiovascular disease
at ≈20% in prediabetes [10]. It is hypothesised that the
diﬀerent prediabetic states have both diﬀerent aetiology
and pathophysiology and that individualised prevention
and treatment strategies should be assessed based on the
prediabetic subtype [10, 11]. Diﬀerent diagnostic criteria
with varying cut-points exist and have changed through
time [1, 10, 15, 16].
4.3. The Relation between GLP-1 and Prediabetes. Based on
the literature search in PubMed, 19 original articles are
PubMed search conducted on 
10 March 2017
298 articles
60 articles
Included: 19 articles
Evaluation based on title
Evaluation based on abstract
Excluded: n = 238
(i) Irrelevant: 230
(ii) Language: 8
Excluded: n = 41
Identification of articles
Inclusion criteria:
Article investigating the relation
between GLP-1 and prediabetic
subtypes.
⁎Articles with inadequate or
indefinite titles were included for
further evaluation.
Exclusion criteria:
Articles irrelevant in proportion to
answering the research question or
due to languages other than
English.
⁎
Figure 1: Flowchart of the search process. See text for details.
Pancreas
Gut and
brain
Glucagon-like peptide-1 (total)
DPP IV
9
9 – 36NH2
9 – 37
7
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Figure 2: GLP-1 isoforms—illustration from Bak et al. [8].
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included in assessing the relation between GLP-1 and predi-
abetes. In the following, these articles will be reviewed.
The included studies were published between 1997 and
2016. Not all studies investigated all the diﬀerent subtypes
of prediabetes described above. For clarity, and since it
appears that the diﬀerent subtypes have both diﬀerent aetiol-
ogy and pathophysiology [10, 11], the results will be reviewed
in order of subtype. The included studies are not consistent
in the terms used to describe the prediabetic subtype (i-IFG
or IFG and i-IGT or IGT). The term used when assessing
an included study is the one used in the respective study.
An overview of the results can be seen in Table 1.
4.3.1. Stimulus. All studies, except two [17, 18], conducted a
75 g OGTT measuring GLP-1, and other variables, at various
time points. Fernandez-Garcia et al. [17] conducted a 60 g
high-fat meal and Toft-Nielsen et al. [18] conducted a mixed
breakfast meal containing 2250 kJ.
Besides the 75 g OGTT, six studies [19–24] conducted
additional tests on the same participants: Yabe et al. [19]
and Lee et al. [20] conducted a meal tolerance test (MTT)
(480 kcal, carbohydrate : protein : fat = 2.8 : 1 : 1). Vollmer
et al. [24] conducted a mixed meal challenge (820 kcal, carbo-
hydrate : protein : fat = 3.38 : 1 : 3.30). Faerch et al. [21] and
Laakso et al. [23] conducted an intravenous glucose toler-
ance test (IVGTT) to measure ﬁrst-phase insulin secretion
and a 120min hyperinsulinaemic-euglycaemic clamp to
measure peripheral insulin sensitivity. Muscelli et al. [22]
conducted an isoglycaemic intravenous glucose test to assess
the incretin eﬀect.
4.3.2. “Active/Intact” or “Total” GLP-1. The included studies
have measured both “active/intact” and “total” GLP-1 (and
eventually the small amount of GLP-1(1–36)NH2 and GLP-
1(1–37) although not mentioned in any of the studies).
Four studies measured “active/intact” GLP-1 only
[17, 20, 25, 26], thirteen studies measured “total” GLP-1 only
[7, 9, 11, 18, 22–24, 27–32], and two studies measured both
“active/intact” and “total” GLP-1 [14, 19]. As mentioned ear-
lier and discussed later, measuring “total” GLP-1 is best,
when GLP-1 secretion should be measured [5, 8, 12–14].
The studies measuring “active/intact” GLP-1 only will not
be reviewed in detail, since they are concluding on metabo-
lites which they may not have measured. Results assessing
“active/intact” GLP-1 can be seen in Table 1. Additionally,
when measuring “active” GLP-1, it is advised to use a DPP-
4 inhibitor when collecting blood samples [12]. This was
done in all studies except Fernandez-Garcia et al. [17] which
did not report any use of DPP-4 inhibitor. This could of
course have inﬂuenced the results.
4.3.3. “Total” GLP-1
(1) “Total” GLP-1 and i-IFG/IFG. 6/19 included studies
assessed the relation between “total” GLP-1 and i-IFG/IFG
[9, 14, 21, 23, 27, 29].
Increased: Faerch et al. [21] studied the GLP-1 response
to a 3 h OGTT in 66 subjects. They found no diﬀerence in
fasting GLP-1 between i-IFG and NGT. However, they found
a signiﬁcantly higher 3-hour AUC GLP-1 in i-IFG subjects
compared to NGT subjects. There was a low number of
women in this group (only 2). This could suggest a compen-
satory GLP-1 response in this subgroup.
Unchanged: Hussein et al. [27] studied 80 subjects’
glucose-stimulated GLP-1 response (30 minutes after 75 g
glucose). The subjects were divided into 4 groups: normal
weight NGT, obese NGT, obese IFG, and obese IFG/IGT.
They found no diﬀerence in glucose-stimulated GLP-1
between obese NGT and obese IFG. However, glucose-
stimulated GLP-1 were reduced in all obese groups compared
to the normal weight group. These results indicate that BMI,
not glucose tolerance, inﬂuences 30min-glucose-stimulated
GLP-1 levels.
Zhang et al. [29] studied 531 subjects’ GLP-1 response to
a 2 h OGTT. They only measured GLP-1 at 0 and 120min
and found no diﬀerence in fasting GLP-1, 2 h GLP-1, or
ΔGLP-1 when comparing i-IFG and NGT subjects.
Smushkin et al. [14] studied 165 subjects’ GLP-1
response to a 2 h OGTT. They found no diﬀerence in either
fasting GLP-1, max “total” GLP-1, AUC GLP-1, or AAB
GLP-1 when comparing IFG/NGT and NFG/NGT subjects.
Reduced: Faerch et al. [9] studied 1462 subjects’ response
to a 2 h OGTT. They measured GLP-1 at 0, 30, and 120min
and grouped the subjects in proportion to sex. They found no
diﬀerences in the male i-IFG compared to NGT. However, in
the female groups, they found a reduced rAUC0–30, rAUC0–
120, and iAUC120 when comparing i-IFG and NGT subjects.
This suggests that the GLP-1 response is inﬂuenced by sex.
Laakso et al. [23] studied 278 subjects’ GLP-1 response to
a prolonged 4 h OGTT. All subjects were nondiabetic
oﬀspring of patients with type two diabetes. They found
a reduced GLP-1 response at 15, 90, and 120min and a
reduced AUC0–240 when comparing i-IFG and NGT sub-
jects. This could indicate that being a nondiabetic oﬀ-
spring of a patient with type 2 diabetes could inﬂuence
the GLP-1 response suggesting a genetic component in
the GLP-1 response.
(2) “Total” GLP-1 and i-IGT/IGT. 14/19 included studies
assessed the relation between “total” GLP-1 and i-IGT/IGT
[7, 9, 14, 18, 19, 21–24, 28–32].
Increased: Smushkin et al. [14] also studied the GLP-1
response between NFG/IGT and NFG/NGT. They found
no diﬀerence in fasting GLP-1, max GLP-1, and AUC GLP-
1. However, they found an increased integrated incremental
concentration of GLP-1 (2-hour area above basal (AAB
GLP-1)) when comparing NFG/IGT and NFG/NGT.
Unchanged: Wang et al. [7] studied 80 subjects’ GLP-1
response to a 3 h OGTT. They found no diﬀerence in either
GLP-1 levels at each measured time point, ΔGLP-1, or 3-
hour AUC GLP-1 when comparing IGT and NGT subjects.
Yabe et al. [19] conducted both a 2 h OGTT and a MTT
in 102 subjects. They found no diﬀerence in either fasting
nor postprandial GLP-1 response—both when assessing
GLP-1 levels at each time point and 2hour AUC GLP-
1—between IGT and NGT.
Faerch et al. [21] found no diﬀerence in either fasting
GLP-1 or 3-hour AUC GLP-1 when comparing i-IGT and
NGT subjects.
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Muscelli et al. [22] studied 51 well-matched subjects’
GLP-1 response to a 3 h OGTT. They found no diﬀerence
in GLP-1 levels or 3-hour AUC GLP-1 between IGT and
NGT subjects.
Vollmer et al. [24] studied 48 well-matched subjects’
GLP-1 response to a 4-hour OGTT and a mixed meal. They
found no diﬀerence in GLP-1 levels when comparing IGT
and NGT in both challenges.
Rasket al. [31] studied30well-matchedwomen ina3-hour
OGTT and measured their GLP-1 response. They found no
diﬀerence in fasting GLP-1, GLP-1 levels at each time point,
30min AUC GLP-1, and 120min AUC GLP-1 between IGT
and NGT. However, they found a signiﬁcant diﬀerence when
comparing the “ﬁrst 30 minutes GLP-1 concentration increa-
se’—the increase being reduced in IGT versus NGT. The
30min iAUC GLP-1 also showed a tendency (P = 0 072) to
be reduced in IGT versus NGT. 17 of the women were post-
menopausal, which could have an impact on the results.
Toft-Nielsen et al. [18] studied 102 subjects’ GLP-1
response to a 4-hour mixed meal. They found no diﬀerence
in either fasting GLP-1 or 4-hour AUC GLP-1 (corrected
for BMI and gender) between IGT and NGT subjects.
Ahren et al. [32] studied 13 well-matched postmeno-
pausal women and measured their GLP-1 response in a 2-
hour OGTT. They found no diﬀerence in fasting GLP-1, no
diﬀerence in GLP-1 increase AUC0–60, or GLP-1 decrease
between IGT and NGT.
Reduced: Faerch et al. [9] also measured GLP-1 in i-IGT
subjects. They found a reduced rAUC0–30 and a reduced
rAUC0–60 in women with i-IGT compared to NGT. No dif-
ferences were found between the two groups when assessing
iAUC30 or iAUC60.
Shen et al. [28] studied 43 subjects’ GLP-1 response to a
2-hour OGTT. They found no diﬀerence in fasting GLP-1.
However, GLP-1 levels were reduced at 30, 60, and 90min
and 120min AUC GLP-1 was reduced when comparing
IGT and NGT.
Zhang et al. [29], mentioned above in the i-IFG/IFG part,
found no diﬀerences in fasting GLP-1 or 2 h GLP-1 between
subjects with i-IGT and NGT. However, they found that
ΔGLP-1 was reduced in i-IGT versus NGT.
Nathanson et al. [30] studied 509 71-year-old men and
their GLP-1 response to an OGTT measuring GLP-1 at 0
and 60minutes. They found no reduction in fasting GLP-1
and GLP-1 at 60min. However, ΔGLP-1 was reduced in
IGT compared to NGT subjects.
Laakso et al. [23], also mentioned above, found reduced
GLP-1 levels at 15, 90, and 120 minutes and a reduced
AUC0–240 in i-IGT versus NGT.
(3) “Total” GLP-1 and IFG/IGT. 5/19 included studies
assessed the relation between “total” GLP-1 and IFG/IGT
[9, 14, 23, 27, 29].
Unchanged: Hussein et al. [27] also assessed IFG/IGT
subjects. They found no diﬀerence in the GLP-1 response
in obese IFG/IGT subjects compared to obese NGT.
Smushkin et al. [14] found no diﬀerence in either fasting
or postprandial GLP-1 when comparing both maximal GLP-
1, 2-hour AUC and 2-hour AAB, in IFG/IGT with NFG/NGT.
Reduced: Faerch et al. [9], as mentioned above, stratiﬁed
their subjects according to sex.When comparing IFG/IGTwith
NGT subjects, they found a reduced 120min GLP-1 in both
sexes. Furthermore, they found a reduction in rAUC0–30,
rAUC0–120, and iAUC120 in female subjects with IFG/IGT.
Zhang et al. [29] found a reduced fasting GLP-1 when
comparing IFG/IGT with i-IGT. When comparing IFG/IGT
with both NGT, i-IFG and i-IGT, they found a reduced
2-hour GLP-1 and a reduced ΔGLP-1.
Laakso et al. [23] found a reduced 15, 90, and 120min
GLP-1 and a reduced AUC0–240 when comparing IFG/IGT
with NGT subjects.
4.4. Why Such a Diﬀerence? Summarizing, studies assessing
the “total” GLP-1 (and “active/intact”) response in i-IFG/
IFG and i-IGT/IGT found both increased, unaltered, and
reduced GLP-1 levels when compared with NGT. Studies
assessing IFG/IGT found unaltered or reduced GLP-1 levels
when compared with NGT. Thereby, nearly all possible out-
comes have been reported. So why this diﬀerence?
4.4.1. “Active/Intact” or “Total” GLP-1. As mentioned earlier,
it is argued that “total”GLP-1 is best suited whenGLP-1 secre-
tion should be assessed [5, 8, 12–14]. The choice of measuring
“active/intact” GLP-1 could be one reason of conﬂicting
results. Furthermore, when assessing “active/intact” GLP-1, a
diﬀerence in DPP-4 activity could also have an impact on
the results—although included studies show no diﬀerence in
DPP-4 activity among prediabetic subgroups [14, 19, 20, 26].
4.4.2. Study Design and Duration. All the included studies
were cross-sectional studies except the study by Zheng et al.
[25]. This type of study design is not designed to assess the
duration by which individuals have had prediabetes [21,
33]. This could have inﬂuenced the results, and longitudinal
prospective studies are therefore suggested to assess the
GLP-1 response in the course from NGT over prediabetes
to type 2 diabetes [6, 11, 21, 34]. Only two studies have an
estimate of prediabetes duration: Zheng et al. found a
reduced fasting “active/intact” GLP-1 in prediabetic subjects
that were NGT 4 years earlier, and Faerch et al. [21] studied
individuals that were NGT 5 years earlier ﬁnding no diﬀer-
ence in fasting “total” GLP-1 but found an increased 3-hour
AUC GLP-1 in i-IFG versus NGT. This could suggest a com-
pensatory GLP-1 secretion [21], which could perhaps explain
the increased 2 h AAB “total” GLP-1 response in NFG/IGT
versus NFG/NGT subjects, reported by Smushkin et al. [14].
4.4.3. Diagnostic Criteria. As mentioned earlier, diﬀerent
diagnostic criteria with diﬀerent cut-points for the predia-
betic subtypes exist and have varied through time [1, 10, 15,
16]. The current deﬁnition of IGT from WHO corresponds
to the term IFG/IGT used by many studies [1]. However,
many of the included studies include cut-points to diﬀerenti-
ate between i-IFG, i-IGT, and IFG/IGT although varying
terms are used (i-IFG or IFG and i-IGT or IGT) [9, 11, 14,
17, 19, 23, 27–29]. This could also be a reason for the
diﬀering results. Furthermore, it has been argued that i-IFG
and i-IGT are a continuum of impaired glucose regulation
10 Journal of Diabetes Research
rather than absolute states [11], hence also aﬀecting the
results due to deﬁned diagnostic criteria.
4.4.4. Stimulus.Most of the studies conducted an OGTT, but
three studies conducted an additional meal test, as described
above [19, 20, 24]. The three studies found the same results in
both challenges, suggesting that stimulus is not inﬂuencing
on the diﬀerent results in the included studies. Vollmer
et al. [24] found no signiﬁcant diﬀerence in integrated incre-
mental plasma GLP-1 concentrations when comparing
OGTT with a mixed breakfast meal. Furthermore, peak
GLP-1 were seen after 30 minutes during the OGTT and after
90 minutes during the mixed meal. Yabe et al. [19] reported
that “total” GLP-1 increased only after glucose ingestion
and not after a mixed meal. In contrast to Vollmer et al.,
Lee et al. [20] reported a peak of “active/intact” GLP-1 at
20–30 minutes in both challenges, concentrations after the
OGTT: 7–9 pmol/l and the MTT: 3–5 pmol/l, and a signif-
icantly greater iAUC GLP-1 in OGTT versus MTT. This
diﬀerence could be explained by the diﬀerent meal compo-
sitions or measuring technique.
4.4.5. Study Size. The study size in the included studies varied
from 13 to 1462. A lot of the studies are therefore limited by
their sample size. When assessing the ﬁve studies with the
largest sample sizes (>200 subjects) [9, 23, 25, 29, 30], it sug-
gests a reduced GLP-1 response (for details, see Table 1) in
IFG/IGT. Altering results are reported in the i-IFG/IFG and
i-IGT/IGT groups due to, for example, sample times, diﬀer-
ing analytical methods, and sex. This strongly suggests an
alteration in the GLP-1 response in the IFG/IGT group.
4.4.6. Assays. Diﬀerences in assays may have inﬂuenced the
results, both in relation to epitope (e.g., “active/intact” or
“total” GLP-1) and selected commercially available kits [8,
12]. Regarding epitope, Smushkin et al. [14] used a diﬀerent
approach to measure “total” GLP-1 by measuring active and
inactive GLP-1 and add the two to get the “total” GLP-1. By
choosing that approach, they might have avoided the detec-
tion of the small amounts of GLP-1(1–36)NH2/(1–37)
secreted from the pancreas, which all C-terminally speciﬁc
antibodies might detect [12]. The plethora of selected
kits in diﬀerent studies might also have inﬂuenced the results
[8]. Interestingly, Zhang et al. [29] used a kit, which Bak et al.
[8] found not to detect any GLP-1 isoforms in both
plasma or buﬀer.
4.4.7. Sampling Time. Sampling time might also be a reason
for the diﬀerence in reported results. Both the OGTT dura-
tion and the sampling interval varied considerable between
studies. With large intervals, the peak GLP-1 might be missed
emphasizing frequent sampling in future studies [34]. Peak
GLP-1 could vary with varying glucose tolerance status [14]
or gastric emptying [34].
4.4.8. Sex. Faerch et al. [9] found a higher 30 and 120min,
tAUC, and rAUC GLP-1 response in women compared to
men, when adjusting for BMI, height, and weight. This is
supported by Vollmer et al. [24] reporting higher GLP-1
plasma concentrations in women compared to men in both
an OGTT and a mixed meal and by Toft-Nielsen et al. [18]
reporting a reduced AUC GLP-1 in males. If not corrected,
this could also be a reason of the diﬀerent results.
4.4.9. BMI. Faerch et al. [9] also found a relation between
BMI and the GLP-1 response, reporting a reduced
rAUC0–30, rAUC0–120, iAUC0–30, and iAUC0–120 in both
overweight and obese compared to normal weight individ-
uals, and adjusted for glucose tolerance status, age, and
sex. This is supported by several other included studies
[18, 22, 24, 27]. Not all studies had matched BMI between
the groups. If not corrected, this could also be a reason of
the diﬀerent results.
4.4.10. Genetics. Laakso et al. [23] found a reduced GLP-1
response in i-IFG, i-IGT, and IFG/IGT. All participants were
nondiabetic oﬀspring of patients with type 2 diabetes. This
could indicate a genetic component in the GLP-1 response
and the development of prediabetes and could further be a
reason of the diﬀering results between the included studies.
4.4.11. Ethnicity. The included studies are conducted in dif-
ferent ethnic groups. This could also have an impact on the
diﬀering results [21, 35].
4.4.12. Analytical Methods. Diﬀerent analytical methods can
also have inﬂuenced the results between the studies [9].
Faerch et al. [9], for example, used rAUC, not used in any
of the other studies.
4.4.13. Age. Faerch et al. [9] also reported a relation between
GLP-1 and age, with an increasing—although small—GLP-1
response with increasing age. If not corrected, this could also
explain the diﬀering results.
4.4.14. Other Factors. Other factors could also have an inﬂu-
ence on the GLP-1 response, for example, insulin resis-
tance [17, 36], glucagon levels [6], and nonesteriﬁed
fatty acid levels [6, 24].
4.5. Potential Mechanisms for the Eventually Reduced GLP-1
Response in Prediabetes. Rask et al. [36] have found a reduced
GLP-1 secretion in response to a mixed meal in nondiabetic
men with insulin resistance. This suggests an association
between insulin resistance and GLP-1 secretion. In vitro
studies of models of L cells have shown that L cells express
the insulin receptor [37]. Furthermore, in vitro studies have
shown a stimulatory eﬀect of insulin on the GLP-1 secretion
in L cell models in a glucose-dependent manner [37, 38]. In
continuation of the study by Rask et al. [36], in vitro and
in vivo studies have showed reduced homologous and heter-
ologous secretagogue-induced GLP-1 secretion in insulin
resistant L cell models [37]. A study by Iepsen et al. [39]
showed an increase in the meal-induced secretion of GLP-1
after a 1-year 13% body weight loss maintenance accom-
panied by a signiﬁcant improvement in the HOMA-IR
[39] further indicating that the L cell might be insulin sensi-
tive [9, 39]. This potential mechanism could diﬀer between
the prediabetic subtypes since the site of insulin resistance
is hypothesised to be diﬀerent with increased hepatic glucose
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production in IFG and a reduced peripheral glucose disposal
in IGT [10, 11].
In vitro studies have also shown a glucotoxic eﬀect on
the GLUTag L cell model reducing acute glucose-induced
GLP-1 secretion [40] and a lipotoxic eﬀect on the GLUTag
L cell model aﬀecting L cell viability, with a presumed
counteractive eﬀect of insulin and the GLP-1 analog
Exendin-4 [38].
Furthermore, in vitro studies have shown that chronic
exposure to the proinﬂammatory cytokine TNFα reduces
both GLP-1 expression and secretion from L cell models
expressing the TNFα-receptor TNFR1 [41]. This could indi-
cate a role of these extracellular metabolites and TNFα on the
potentially reduced GLP-1 secretory response in prediabetes.
Returning to the research question, Is a low GLP-1
response a predictor of prediabetes in adults?When assessing
the ﬁve studies with the largest sample size, it clearly suggests
an alteration in the GLP-1 response in IFG/IGT subjects and
varying results when assessing the two other subtypes—i-
IFG/IFG and i-IGT/IGT. However, varying results have been
reported in all subtypes and warrants further studies. Possi-
ble reasons for the varying results have been discussed. As
mentioned above, the need for longitudinal prospective stud-
ies are necessary to assess the impact of duration of the pre-
diabetic state on the GLP-1 response in prediabetes and to
determine the, eventual, temporal inﬂuence of the GLP-1
response in the pathogenesis of type 2 diabetes. Additionally,
the aim of this review is to survey the studies assessing the
relation between the GLP-1 response and the diﬀerent
prediabetic subtypes and to suggest potential confounders
relevant when conducting future studies. An eventual limita-
tion of this review is that only the PubMed database was
assessed. Furthermore, relevant studies could have been
excluded in the search or in the evaluation of relevant studies.
To avoid the exclusion of studies, a broad search was con-
ducted including many synonyms for the rather broad
term “prediabetes.”
5. Conclusion
Conclusively, this review suggests that the GLP-1 response
is a variable in prediabetes possibly due to a varying GLP-
1-secreting proﬁle during the development and progression
of type 2 diabetes or diﬀerence in the measurement tech-
nique. Longitudinal prospective studies are needed to assess
whether a reduced GLP-1 response is a predictor of diabe-
tes. Furthermore, this review gives an overview of studies
assessing the relation between GLP-1 and prediabetes and
discusses possible confounding factors, relevant when con-
ducting future studies.
Abbreviations
IGT: Impaired glucose tolerance
IFG: Impaired fasting glucose
i-IGT: Isolated impaired glucose tolerance
i-IFG: Isolated impaired fasting glucose
rAUC: Relative area under the curve
iAUC: Incremental area under the curve
tAUC: Total area under the curve
GLUTag L
cell model:
A GLP-1-secreting cell line (source: glucagon-
producing enteroendocrine cell tumor that arose
in transgenicmice generated on an outbredCD-1
background [38]).
Conflicts of Interest
The authors declare that there is no conﬂict of interest
regarding the publication of this article.
References
[1] World Health Organization, Global Report on Diabetes, World
Health Organization, Geneva, Switzerland, 2016.
[2] C. Bommer, E. Heesemann, V. Sagalova et al., “The global
economic burden of diabetes in adults aged 20-79 years: a
cost-of-illness study,” The Lancet Diabetes and Endocrinology,
vol. 5, no. 6, pp. 423–430, 2017.
[3] C. F. Deacon and B. Ahren, “Physiology of incretins in health
and disease,” The Review of Diabetic Studies, vol. 8, no. 3,
pp. 293–306, 2011.
[4] M. Nauck, F. Stockmann, R. Ebert, and W. Creutzfeldt,
“Reduced incretin eﬀect in type 2 (non-insulin-dependent)
diabetes,” Diabetologia, vol. 29, no. 1, pp. 46–52, 1986.
[5] S. Calanna, M. Christensen, J. J. Holst et al., “Secretion of
glucagon-like peptide-1 in patients with type 2 diabetes melli-
tus: systematic review and meta-analyses of clinical studies,”
Diabetologia, vol. 56, no. 5, pp. 965–972, 2013.
[6] M. A. Nauck, I. Vardarli, C. F. Deacon, J. J. Holst, and J. J.
Meier, “Secretion of glucagon-like peptide-1 (GLP-1) in type
2 diabetes: what is up, what is down?,” Diabetologia, vol. 54,
no. 1, pp. 10–18, 2011.
[7] X. L. Wang, F. Ye, J. Li et al., “Impaired secretion of glucagon-
like peptide 1 during oral glucose tolerance test in patients with
newly diagnosed type 2 diabetes mellitus,” Saudi Medical
Journal, vol. 37, no. 1, pp. 48–54, 2016.
[8] M. J. Bak, N. J. Wewer Albrechtsen, J. Pedersen et al., “Speciﬁc-
ity and sensitivity of commercially available assays for
glucagon-like peptide-1 (GLP-1): implications for GLP-1 mea-
surements in clinical studies,”Diabetes, Obesity &Metabolism,
vol. 16, no. 11, pp. 1155–1164, 2014.
[9] K. Faerch, S. S. Torekov, D. Vistisen et al., “GLP-1 response to
oral glucose is reduced in prediabetes, screen-detected type 2
diabetes, and obesity and inﬂuenced by sex: the ADDITION-
PRO study,” Diabetes, vol. 64, no. 7, pp. 2513–2525, 2015.
[10] L. Perreault and K. Faerch, “Approaching pre-diabetes,”
Journal of Diabetes and its Complications, vol. 28, no. 2,
pp. 226–233, 2014.
[11] K. Faerch, K. Borch-Johnsen, J. J. Holst, and A. Vaag, “Patho-
physiology and aetiology of impaired fasting glycaemia and
impaired glucose tolerance: does it matter for prevention and
treatment of type 2 diabetes?,” Diabetologia, vol. 52, no. 9,
pp. 1714–1723, 2009.
[12] C. F. Deacon and J. J. Holst, “Immunoassays for the
incretin hormones GIP and GLP-1,” Best Practice & Research.
Clinical Endocrinology & Metabolism, vol. 23, no. 4, pp. 425–
432, 2009.
[13] J. J. Holst, “The physiology of glucagon-like peptide 1,” Physi-
ological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007.
12 Journal of Diabetes Research
[14] G. Smushkin, A. Sathananthan, C. D. Man et al., “Defects in
GLP-1 response to an oral challenge do not play a signiﬁcant
role in the pathogenesis of prediabetes,” The Journal of Clinical
Endocrinology and Metabolism, vol. 97, no. 2, pp. 589–598,
2012.
[15] American Diabetes A, “Diagnosis and classiﬁcation of diabetes
mellitus,” Diabetes Care, vol. 33, Supplement 1, pp. S62–S69,
2010.
[16] World Health Organization and International Diabetes
Federation, Deﬁnition and Diagnosis of Diabetes Mellitus and
IntermediateHyperglycaemia : Report of aWHO/IDFConsulta-
tion, World Health Organization, Geneva, Switzerland, 2006.
[17] J. C. Fernandez-Garcia, M. Murri, L. Coin-Araguez, J. Alcaide,
R. El Bekay, and F. J. Tinahones, “GLP-1 and peptide YY secre-
tory response after fat load is impaired by insulin resistance,
impaired fasting glucose and type 2 diabetes in morbidly obese
subjects,” Clinical Endocrinology (Oxford), vol. 80, no. 5,
pp. 671–676, 2014.
[18] M. B. Toft-Nielsen, M. B. Damholt, S. Madsbad et al., “Deter-
minants of the impaired secretion of glucagon-like peptide-1
in type 2 diabetic patients,” The Journal of Clinical Endocrinol-
ogy and Metabolism, vol. 86, no. 8, pp. 3717–3723, 2001.
[19] D. Yabe, A. Kuroe, K. Watanabe et al., “Early phase glucagon
and insulin secretory abnormalities, but not incretin secretion,
are similarly responsible for hyperglycemia after ingestion of
nutrients,” Journal of Diabetes and its Complications, vol. 29,
no. 3, pp. 413–421, 2015.
[20] S. Lee, D. Yabe, K. Nohtomi et al., “Intact glucagon-like peptide-
1 levels are not decreased in Japanese patients with type 2
diabetes,” Endocrine Journal, vol. 57, no. 2, pp. 119–126, 2010.
[21] K. Faerch, A. Vaag, J. J. Holst, C. Glumer, O. Pedersen, and
K. Borch-Johnsen, “Impaired fasting glycaemia vs impaired
glucose tolerance: similar impairment of pancreatic alpha
and beta cell function but diﬀerential roles of incretin hor-
mones and insulin action,” Diabetologia, vol. 51, no. 5,
pp. 853–861, 2008.
[22] E. Muscelli, A. Mari, A. Casolaro et al., “Separate impact of
obesity and glucose tolerance on the incretin eﬀect in normal
subjects and type 2 diabetic patients,” Diabetes, vol. 57, no. 5,
pp. 1340–1348, 2008.
[23] M. Laakso, J. Zilinskaite, T. Hansen et al., “Insulin sensitivity,
insulin release and glucagon-like peptide-1 levels in persons
with impaired fasting glucose and/or impaired glucose toler-
ance in the EUGENE2 study,” Diabetologia, vol. 51, no. 3,
pp. 502–511, 2008.
[24] K. Vollmer, J. J. Holst, B. Baller et al., “Predictors of incretin
concentrations in subjects with normal, impaired, and diabetic
glucose tolerance,” Diabetes, vol. 57, no. 3, pp. 678–687, 2008.
[25] T. Zheng, Y. Gao, A. Baskota, T. Chen, X. Ran, and H. Tian,
“Increased plasma DPP4 activity is predictive of prediabetes
and type 2 diabetes onset in Chinese over a four-year period:
result from the China National Diabetes and Metabolic Dis-
orders Study,” The Journal of Clinical Endocrinology and
Metabolism, vol. 99, no. 11, pp. E2330–E2334, 2014.
[26] L. Pala, S. Ciani, I. Dicembrini et al., “Relationship between
GLP-1 levels and dipeptidyl peptidase-4 activity in diﬀerent
glucose tolerance conditions,” Diabetic Medicine, vol. 27,
no. 6, pp. 691–695, 2010.
[27] M. S. Hussein, M. M. Abushady, S. Refaat, and R. Ibrahim,
“Plasma level of glucagon-like peptide 1 in obese Egyptians
with normal and impaired glucose tolerance,” Archives of
Medical Research, vol. 45, no. 1, pp. 58–62, 2014.
[28] J. Shen, Z. Chen, C. Chen, X. Zhu, and Y. Han, “Impact of
incretin on early-phase insulin secretion and glucose excur-
sion,” Endocrine, vol. 44, no. 2, pp. 403–410, 2013.
[29] F. Zhang, X. Tang, H. Cao et al., “Impaired secretion of total
glucagon-like peptide-1 in people with impaired fasting glu-
cose combined impaired glucose tolerance,” International
Journal of Medical Sciences, vol. 9, no. 7, pp. 574–581, 2012.
[30] D. Nathanson, B. Zethelius, C. Berne, J. J. Holst, A. Sjoholm,
and T. Nystrom, “Reduced plasma levels of glucagon-like
peptide-1 in elderly men are associated with impaired glucose
tolerance but not with coronary heart disease,” Diabetologia,
vol. 53, no. 2, pp. 277–280, 2010.
[31] E. Rask, T. Olsson, S. Soderberg et al., “Insulin secretion and
incretin hormones after oral glucose in non-obese subjects
with impaired glucose tolerance,” Metabolism, vol. 53, no. 5,
pp. 624–631, 2004.
[32] B. Ahren, H. Larsson, and J. J. Holst, “Reduced gastric inhibi-
tory polypeptide but normal glucagon-like peptide 1 response
to oral glucose in postmenopausal women with impaired glu-
cose tolerance,” European Journal of Endocrinology, vol. 137,
no. 2, pp. 127–131, 1997.
[33] M. J. Theodorakis, “Comment on Faerch et al. GLP-1 response
to oral glucose is reduced in prediabetes, screen-detected type
2 diabetes, and obesity and inﬂuenced by sex: the ADDITION-
PRO study. Diabetes 2015;64:2513-2525,” Diabetes, vol. 64,
no. 9, pp. e28–e29, 2015, discussion e30-1.
[34] A. Vella and C. Cobelli, “Defective glucagon-like peptide 1
secretion in prediabetes and type 2 diabetes is inﬂuenced by
weight and sex. Chicken, egg, or none of the above?,” Diabetes,
vol. 64, no. 7, pp. 2324-2325, 2015.
[35] A. K. Singh, “Glucagon-like peptide 1 and dysglycemia:
conﬂict in incretin science,” Indian Journal of Endocrinology
and Metabolism, vol. 19, no. 1, pp. 182–187, 2015.
[36] E. Rask, T. Olsson, S. Soderberg et al., “Impaired incretin
response after a mixed meal is associated with insulin resis-
tance in nondiabetic men,” Diabetes Care, vol. 24, no. 9,
pp. 1640–1645, 2001.
[37] G. E. Lim, G. J. Huang, N. Flora, D. LeRoith, C. J. Rhodes, and
P. L. Brubaker, “Insulin regulates glucagon-like peptide-1
secretion from the enteroendocrine L cell,” Endocrinology,
vol. 150, no. 2, pp. 580–591, 2009.
[38] C. Kappe, Q. Zhang, J. J. Holst, T. Nystrom, and A. Sjoholm,
“Evidence for paracrine/autocrine regulation of GLP-1-
producing cells,” American Journal of Physiology Cell Physiol-
ogy, vol. 305, no. 10, pp. C1041–C1049, 2013.
[39] E. W. Iepsen, J. Lundgren, J. J. Holst, S. Madsbad, and
S. S. Torekov, “Successful weight loss maintenance includes
long-term increased meal responses of GLP-1 and PYY3-36,”
European Journal of Endocrinology, vol. 174, no. 6, pp. 775–
784, 2016.
[40] F. Urbano, A. Filippello, A. PinoDi et al., “Altered expression
of uncoupling protein 2 in GLP-1-producing cells after
chronic high glucose exposure: implications for the pathogen-
esis of diabetes mellitus,” American Journal of Physiology.
Cell Physiology, vol. 310, no. 7, pp. C558–C567, 2016.
[41] J. Gagnon, M. Sauve, W. Zhao et al., “Chronic exposure
to TNFα impairs secretion of glucagon-like peptide-1,” Endo-
crinology, vol. 156, no. 11, pp. 3950–3960, 2015.
13Journal of Diabetes Research
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
